Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Toxocara Canis Increases the Potential of Breast Cancer by Reducing the Expression of the P53 Protein

Author(s): Forough Kazemi, Hemen Moradi-Sardareh, Reza Arjmand, Mehdi Tavalla*, Afshin Amari and Bahman Cheraghian

Volume 24, Issue 3, 2024

Published on: 14 April, 2023

Page: [335 - 343] Pages: 9

DOI: 10.2174/1566524023666230320103506

Price: $65

Abstract

Introduction: Breast cancer is considered the most frequent type of cancer in women with high mortality worldwide, and most importantly, it is the second most common cancer. However, some breast cancer-related risk factors remain unknown. So, the current study was designed to evaluate the effect of Toxocara canis on the biomarkers correlated with proliferation, apoptosis, inflammation, and angiogenesis in 4T1 tumor-bearing mice infected with Toxocara canis for the first time.

Methods: Mice were categorized into four groups: A) control, B) treated with 4T1+ Toxocara canis, C) treated with Toxocara canis, and D) treated with 4T1. The expression of Ki-67 and P53 was then evaluated by using the immunohistochemical technique. In addition, the levels of transforming growth factor-β, Interferon gamma-γ, Interleukin 10, tumor necrosis factor-α and vascular endothelial growth factor as well as anti- Toxocara canis IgG were determined using the enzyme-linked immunosorbent assay method.

Results: The expression of Ki-67 was significantly increased in the 4T1+ Toxocara canis group than control and Toxocara canis groups (P < 0.001 and P < 0.001, respectively). Moreover, a significant decrease in P53 was found in the 4T1+ Toxocara canis group than in the control and Toxocara canis groups (P < 0.001 and P < 0.001, respectively). Also, the 4T1+ Toxocara canis group significantly reduced the expression of P53 more than 4T1 tumor-bearing mice (P = 0.005). In addition, the 4T1+ Toxocara canis group had an increasing tumor necrosis factor-α and vascular endothelial growth factor than controls (P = 0.004 and P = 0.002, respectively). Furthermore, a significant reduction in Interleukin 10 was found in the 4T1+ Toxocara canis group than in the control group (P = 0.004).

Conclusion: Our findings showed that Toxocara canis could probably increase the potential of breast cancer by reducing P53 in 4T1 tumor-bearing mice infected with Toxocara canis more than other groups.

« Previous Next »
[1]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
Sadegh-Nejadi S, Afrisham R, Emamgholipour S, et al. Influence of plasma circulating exosomes obtained from obese women on tumorigenesis and tamoxifen resistance in MCF ‐7 cells. IUBMB Life 2020; 72(9): 1930-40.
[http://dx.doi.org/10.1002/iub.2305] [PMID: 32542981]
[3]
Ruiz-Manzano RA, Palacios-Arreola MI, Hernández-Cervantes R, et al. Potential novel risk factor for breast cancer: Toxocara canis infection increases tumor size due to modulation of the tumor immune microenvironment. Front Oncol 2020; 10: 736.
[http://dx.doi.org/10.3389/fonc.2020.00736] [PMID: 32547942]
[4]
Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta 2015; 1856(1): 73-85.
[PMID: 26071880]
[5]
Palacios-Arreola MI, Nava-Castro KE, Río-Araiza VHD, Pérez-Sánchez NY, Morales-Montor J. A single neonatal administration of Bisphenol A induces higher tumour weight associated to changes in tumour microenvironment in the adulthood. Sci Rep 2017; 7(1): 10573.
[http://dx.doi.org/10.1038/s41598-017-10135-1] [PMID: 28874690]
[6]
Alipour M. Molecular mechanism of Helicobacter pylori-induced gastric cancer. J Gastrointest Cancer 2021; 52(1): 23-30.
[http://dx.doi.org/10.1007/s12029-020-00518-5] [PMID: 32926335]
[7]
Arcia Franchini AP, Iskander B, Anwer F, et al. The role of chlamydia trachomatis in the pathogenesis of cervical cancer. Cureus 2022; 14(1): e21331.
[PMID: 35186589]
[8]
She Y, Nong X, Zhang M, Wang M. Epstein-Barr virus infection and oral squamous cell carcinoma risk: A meta-analysis. PLoS One 2017; 12(10): e0186860.
[http://dx.doi.org/10.1371/journal.pone.0186860] [PMID: 29065191]
[9]
Jørgensen KR, Jensen JB. Human papillomavirus and urinary bladder cancer revisited. Acta Pathol Microbiol Scand Suppl 2020; 128(2): 72-9.
[http://dx.doi.org/10.1111/apm.13016] [PMID: 31990119]
[10]
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob Health 2016; 4(9): e609-16.
[http://dx.doi.org/10.1016/S2214-109X(16)30143-7] [PMID: 27470177]
[11]
Machicado C, Marcos LA. Carcinogenesis associated with parasites other than schistosoma, opisthorchis and clonorchis: A systematic review. Int J Cancer 2016; 138(12): 2915-21.
[http://dx.doi.org/10.1002/ijc.30028] [PMID: 26840624]
[12]
Botelho MC, Veiga I, Oliveira PA, et al. Carcinogenic ability of Schistosoma haematobium possibly through oncogenic mutation of KRAS gene. Adv Cancer Res Treat 2013; 2013: 876585.
[PMID: 25221779]
[13]
Pastille E, Frede A, McSorley HJ, et al. Intestinal helminth infection drives carcinogenesis in colitis-associated colon cancer. PLoS Pathog 2017; 13(9): e1006649.
[http://dx.doi.org/10.1371/journal.ppat.1006649] [PMID: 28938014]
[14]
Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU. Human toxocariasis: Diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann Trop Med Parasitol 2010; 104(1): 3-23.
[http://dx.doi.org/10.1179/136485910X12607012373957] [PMID: 20149289]
[15]
Kazemi F, Arjmand R, Fallahizadeh S, Tavalla M. Comparison of the detection of Toxocara spp. in the soils of public parks of Ahvaz (southwest of Iran) by PCR and loop-mediated isothermal amplification (LAMP). Infect Disord Drug Targets 2021; 21(3): 375-83.
[http://dx.doi.org/10.2174/1871526520666200715100433] [PMID: 32669079]
[16]
Moura MQ, Macedo MRP, Terto WDS, et al. Detection of Toxocara canis DNA in tissues of experimentally infected mice. Acta Trop 2018; 187: 51-6.
[http://dx.doi.org/10.1016/j.actatropica.2018.07.017] [PMID: 30053384]
[17]
Zibaei M, Sadjjadi SM, Maraghi S. The occurrence of Toxocara species in naturally infected broiler chickens revealed by molecular approaches. J Helminthol 2017; 91(5): 633-6.
[http://dx.doi.org/10.1017/S0022149X16000559] [PMID: 27571878]
[18]
Ruiz-Manzano RA, Hernández-Cervantes R, Del Río-Araiza VH, Palacios-Arreola MI, Nava-Castro KE, Morales-Montor J. Immune response to chronic Toxocara canis infection in a mice model. Parasite Immunol 2019; 41(12): e12672.
[http://dx.doi.org/10.1111/pim.12672] [PMID: 31557337]
[19]
Saki J, Mowla K, Arjmand R, Kazemi F, Fallahizadeh S. Prevalence of Toxoplasma gondii and Toxocara canis among myositis patients in the Southwest of Iran. Infect Disord Drug Targets 2021; 21(1): 43-8.
[http://dx.doi.org/10.2174/1871526520666191231123159] [PMID: 31889500]
[20]
Schonk DM, Kuijpers HJH, van Drunen E, et al. Assignment of the gene(s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10. Hum Genet 1989; 83(3): 297-9.
[http://dx.doi.org/10.1007/BF00285178] [PMID: 2571566]
[21]
Shirendeb U, Hishikawa Y, Moriyama S, et al. Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem 2009; 42(6): 181-90.
[http://dx.doi.org/10.1267/ahc.09030] [PMID: 20126571]
[22]
Hooghe B, Hulpiau P, van Roy F, De Bleser P. ConTra: A promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res 36(Web Server issue) 2008; (Suppl. 2): W128-32.
[http://dx.doi.org/10.1093/nar/gkn195] [PMID: 18453628]
[23]
Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers 2021; 13(17): 4455.
[http://dx.doi.org/10.3390/cancers13174455] [PMID: 34503265]
[24]
Miller I, Min M, Yang C, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep 2018; 24(5): 1105-12.e5.
[http://dx.doi.org/10.1016/j.celrep.2018.06.110]
[25]
Ishihara M, Mukai H, Nagai S, et al. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: Effects of biologic subtype and Ki67 overexpression on survival. Oncology 2013; 84(3): 135-40.
[http://dx.doi.org/10.1159/000345321] [PMID: 23235554]
[26]
Sorbye SW, Kilvaer TK, Valkov A, et al. Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One 2012; 7(10): e47068.
[http://dx.doi.org/10.1371/journal.pone.0047068] [PMID: 23071715]
[27]
Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 2014; 17(1): 40-6.
[http://dx.doi.org/10.4048/jbc.2014.17.1.40] [PMID: 24744796]
[28]
Linzer DIH, Levine AJ. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17(1): 43-52.
[http://dx.doi.org/10.1016/0092-8674(79)90293-9] [PMID: 222475]
[29]
Zhao L, Sanyal S. p53 isoforms as cancer biomarkers and therapeutic targets. Cancers 2022; 14(13): 3145.
[http://dx.doi.org/10.3390/cancers14133145] [PMID: 35804915]
[30]
Hernández BLJ, El-Deiry WS. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer 2021; 1876(1): 188556.
[http://dx.doi.org/10.1016/j.bbcan.2021.188556] [PMID: 33932560]
[31]
Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 2018; 25(1): 154-60.
[http://dx.doi.org/10.1038/cdd.2017.180] [PMID: 29099487]
[32]
McSorley HJ, Maizels RM. Helminth infections and host immune regulation. Clin Microbiol Rev 2012; 25(4): 585-608.
[http://dx.doi.org/10.1128/CMR.05040-11] [PMID: 23034321]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy